drugset

drugset / Trial / NCT02624375

Immune Response to Shingles Vaccination

NCT02624375 ↗

Phase 4 Completed 10 enrolled University of Washington Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).

Timeline

Start: 2016-02
Primary completion: 2019-11
Completion: 2019-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varivax	Vaccine	0.65 ml	Subcutaneous

Indications